RPRX Stock — Price, Charts & Analysis

Royalty Pharma plc (RPRX) has a trailing P/E of 33.01x and a forward P/E of 10.70x. This places RPRX in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

RPRX trades with 33.01x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether RPRX looks overvalued or undervalued.

RPRX's P/E of 33.01x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

RPRX's trailing EPS is $1.86 and forward EPS is $5.74. Reported earnings growth is -46.30%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Royalty Pharma plc generated for each share. RPRX's trailing EPS is $1.86, and investors usually prefer EPS that is positive and growing over time.

Royalty Pharma plc has a market cap of $35.48B, making RPRX a large-cap stock based on the current market value shown on Worldtickers.

RPRX's latest stock price on Worldtickers is $61.40. The latest move is $0.82 or 1.35%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

RPRX's quote includes a latest price of $61.40. The market open is $60.53. Previous close is $60.58. The intraday range is $60.37 to $61.55.

RPRX is up in the latest quote, with a move of $0.82 or 1.35%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

RPRX generated $2.54B in trailing revenue. Revenue growth is 16.50%, which helps show whether demand is expanding or slowing.

RPRX's revenue growth is 16.50%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, RPRX shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $811.99M.

Gross margin is 95.82%. Margins show how efficiently Royalty Pharma plc turns revenue into profit.

Royalty Pharma plc carries $8.96B and holds $836.99M in cash.

RPRX holds $836.99M on its balance sheet.

RPRX's book value per share is $15.53.

Yes, Royalty Pharma plc pays a dividend of $0.94 per share annually. The dividend yield is 155.00%. The payout ratio is 48.92%.

RPRX's dividend yield is 155.00%. Its payout ratio is 48.92%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for RPRX. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through Royalty Pharma plc's investor relations materials.

RPRX's five-year average dividend yield is 229.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 87.32% of RPRX shares. Insiders hold 6.49% of shares. Ownership mix helps investors understand how much of Royalty Pharma plc is held by professional investors and company insiders.

RPRX has 445.28M shares outstanding. Float shares are 415.41M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for RPRX, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for RPRX is $5.74. Earnings growth is -46.30%. Revenue growth is 16.50%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

RPRX's trailing EPS is $1.86. Forward EPS is $5.74. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

RPRX is in the Healthcare sector. Its earnings multiple is 33.01x. Its latest displayed growth metric is 16.50%. Compare these figures with sector peers before deciding whether Royalty Pharma plc is stronger or weaker than average.

RPRX trades at $61.40. The stock trades at 33.01x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Royalty Pharma plc's fundamentals.

RPRX risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.43, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

RPRX should be compared with companies in Biotechnology. Its earnings multiple is 33.01x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Royalty Pharma plc (RPRX) operates in Healthcare, specifically Biotechnology. Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigat

RPRX trades on NasdaqGS. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

RPRX stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Royalty Pharma plc's official website listed on Worldtickers is www.royaltypharma.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Royalty Pharma plc employs about 100 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Royalty Pharma plc is headquartered in New York, NY, United States. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

RPRX is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

RPRX has traded between $34.08 and $62.13 over the past 52 weeks. At $61.40, it is 1.17% below the high and 80.16% above the low. The 52-week range helps gauge long-term price momentum.

RPRX is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is $57.15 and its 200-day moving average is $47.69.

RPRX's RSI is 64.30. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

RPRX's latest RSI reading is 64.30, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for RPRX is near $56.13. Key resistance is near $62.13. Breaks above resistance or below support can change the short-term technical setup.

RPRX's nearest reported support level is $56.13. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

RPRX's nearest reported resistance level is $62.13. A breakout above resistance can improve momentum, especially when volume confirms the move.

RPRX trades about 3.47M shares daily on average. The latest displayed volume is 1.59M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

RPRX's MACD is 0.29, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

RPRX is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 64.30 (neutral). MACD is bullish. Nearest support is around $56.13. Resistance is around $62.13. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $58.67 (4.65% from price). MA50 is $57.15 (7.43% from price). MA200 is $47.69 (28.75% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. RPRX's MA20 is $58.67. MA50 is $57.15. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

RPRX's pivot is near $61.03. Support is near $56.13. Resistance is near $62.13. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for RPRX is near $59.07. These levels help define risk and possible follow-through zones after a breakout or breakdown.

RPRX's Bollinger range is roughly $55.86 to $61.48. Band width is near 9.58%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

RPRX's ATR-based typical daily range is about 2.31%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 1.59M shares. Average volume is about 3.47M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

RPRX's all-time high shown on Worldtickers is $62.13. Its all-time low is $24.05. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

RPRX has a beta of 0.43, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.